Product image of Nyvepria (Pegfilgrastim) supplied by GNH India

Nyvepria

Active Ingredient:
Pegfilgrastim
Origin:
EU

Nyvepria (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Nyvepria, is a long‑acting colony‑stimulating factor presented as a sterile powder for subcutaneous injection use. It reduces the duration of neutropenia in patients receiving myelosuppressive chemotherapy. GNH India supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH India supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nyvepria is a pegylated filgrastim indicated for neutrophil recovery in chemotherapy‑treated patients.

  • Breast cancer: helps restore neutrophil counts after myelosuppressive regimens.
  • Lung cancer: supports neutrophil recovery following cytotoxic therapy.
  • Non‑Hodgkin lymphoma: reduces the duration of chemotherapy‑induced neutropenia.
  • Small‑cell lung cancer: shortens neutropenia episodes during treatment.
  • Acute myeloid leukemia: assists in neutrophil recovery after intensive chemotherapy.
  • Peripheral blood stem‑cell mobilization: facilitates stem‑cell collection when used with chemotherapy.

How It Works

  • Pegfilgrastim is a polyethylene glycol‑conjugated form of recombinant human granulocyte‑colony stimulating factor (G‑CSF). After subcutaneous administration it binds to the G‑CSF receptor on myeloid progenitor cells, prolonging receptor activation and stimulating proliferation, differentiation and survival of neutrophil precursors, thereby increasing circulating neutrophil counts.

Side Effects

Adverse reactions to pegfilgrastim are reported across a range of severity.

Common Side Effects

  • Bone pain, especially in the long bones.
  • Musculoskeletal discomfort.
  • Injection‑site erythema or pruritus.
  • Fatigue or mild headache.
  • Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

  • Splenic rupture or enlargement.
  • Acute respiratory distress syndrome.
  • Severe allergic reactions including anaphylaxis.
  • Vasculitis or capillary leak syndrome.
  • Unexplained leukocytosis.
  • Thromboembolic events.

Precautions & Warnings

When using Nyvepria, clinicians should consider patient‑specific factors and follow recommended monitoring.

  • Renal impairment: adjust monitoring of blood counts and fluid status.
  • Hepatic dysfunction: observe for prolonged neutropenia recovery.
  • Prior splenic disorders: assess risk of splenic enlargement.
  • Concomitant chemotherapy: coordinate timing to avoid overlapping toxicities.
  • Pregnancy and lactation: evaluate risk‑benefit ratio before use.
  • Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Pegfilgrastim may interact with other agents that affect bone‑marrow function or immune response.

Major Interactions (Avoid)

  • Myelosuppressive chemotherapy given within 24 hours of pegfilgrastim injection.
  • High‑dose corticosteroids administered concurrently.

Moderate Interactions (Monitor Closely)

  • Anticoagulants, due to potential increased bleeding risk from thrombocytopenia.
  • Immunosuppressive biologics, which may blunt neutrophil response.
  • Radiotherapy involving large bone‑marrow fields.
  • Drugs that cause hypersensitivity reactions, requiring close observation.
  • Live vaccines, as immune modulation may affect vaccine efficacy.

Frequently Asked Questions

Nyvepria contains pegfilgrastim, a long‑acting granulocyte‑colony stimulating factor that is used to reduce the duration of neutropenia in patients receiving myelosuppressive chemotherapy. It helps maintain adequate neutrophil counts, decreasing infection risk during cancer treatment.

Pegfilgrastim binds to the G‑CSF receptor on bone‑marrow progenitor cells, stimulating their proliferation and maturation into functional neutrophils. The pegylation prolongs its circulating half‑life, providing sustained stimulation of neutrophil production after a single subcutaneous dose.

The dose of Nyvepria is individualized by the prescribing clinician based on the patient’s body weight, chemotherapy regimen and clinical condition. The prescriber determines the exact amount and timing according to approved labeling and local practice guidelines.

Safety data for pegfilgrastim in pregnancy are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be present in milk.

To order Nyvepria, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Nyvepria (pegfilgrastim) is a long‑acting formulation, requiring a single injection per chemotherapy cycle, whereas non‑pegylated filgrastim products need daily dosing. Both classes stimulate neutrophil production, but pegfilgrastim’s extended half‑life offers greater convenience and comparable efficacy in neutropenia prevention.

Nyvepria should be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. It should remain in its original packaging until reconstituted for injection.

Nyvepria is supplied as a sterile powder for subcutaneous injection. After reconstitution with the supplied diluent, the solution is injected under the skin, typically in the abdomen or thigh, according to the prescriber’s instructions.

Serious adverse events include splenic rupture, acute respiratory distress syndrome, severe allergic reactions such as anaphylaxis, and rare cases of vasculitis or capillary leak syndrome. Patients should be monitored for signs of these conditions and receive prompt medical attention if they occur.

Nyvepria is contraindicated in patients with a known hypersensitivity to pegfilgrastim or any of its excipients, and in individuals with a history of splenic rupture. Caution is also advised for patients with severe renal or hepatic impairment, and it should be used only after careful risk‑benefit assessment in pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pegfilgrastim

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT